Jing Qian
Presidente presso Arctic Vision (Shanghai) Biotechnology Co., Ltd.
Provenienza dei contatti di primo grado di Jing Qian
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Arctic Vision (Shanghai) Biotechnology Co., Ltd.
 Arctic Vision (Shanghai) Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a Chinese Shanghai-based ophthalmic biotech company that focuses on developing innovative therapies to address unmet clinical needs and benefit ophthalmic patients. The company is led by an elite team of ophthalmic industry veterans with substantial experience in R&D and commercialization of eye care products. Arctic Vision has top-tier biotech venture capital investors with a broad network in both the U.S. and European ophthalmic markets, and an unprecedented track record in company incubation. The company was founded by Hai Di Hu, who has been the CEO since incorporation.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Jing Qian tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Loyal Valley Capital Co. Ltd.
 Loyal Valley Capital Co. Ltd. Investment ManagersFinance Loyal Valley Capital Co. Ltd (LVC) is an independent private equity firm founded by Li Jun Lin in 2015. The firm is headquartered in Shanghai, China. | Investment Managers | Private Equity Investor | |
Regor Therapeutics Group
 Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | Miscellaneous Commercial Services | Director/Board Member | |
| Fudan University | College/University | Graduate Degree | |
| Renmin University of China | College/University | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Cina | 4 |
| Stati Uniti | 2 |
Settori
| Consumer Services | 3 |
| Finance | 2 |
| Commercial Services | 2 |
Posizioni
| Director/Board Member | 4 |
| Private Equity Investor | 1 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
| Chief Executive Officer | 1 |
Contatti più connessi
| Insiders | |
|---|---|
| Ling Xu | 5 |
| Hai Di Hu | 1 |
| Lu Huang | 1 |
- Borsa valori
- Insiders
- Jing Qian
- Connessioni Società
